BRCA1 and ovarian carcinoma: In this regard, the clinical actionability of multigene panels testing for HBOC assessment has been evaluated; indeed, the use of expanded panels is able to identify more at-risk patients with respect to BRCA1/2 testing alone, and can provide useful information for both patient monitoring and familial testing, especially if the additional pathogenic variants are identified in the most common moderate-risk genes for breast and ovarian cancers, such as CHEK2 and PALB2 [31].